✦ LIBER ✦

Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion

✍ Scribed by Erika Hamilton, Kimberly Blackwell, Amy C Hobeika…

Book ID: 120690400
Publisher: BioMed Central
Year: 2013
Tongue: English
Weight: 96 KB
Volume: 11
Category: Article
ISSN: 1479-5876
DOI: 10.1186/1479-5876-11-82

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I clinical trial of HER2-specific

Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion

✍ Erika Hamilton; Kimberly Blackwell; Amy C Hobeika; Timothy M Clay; Gloria Broadw 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 252 KB

Early Results of Phase 1 Trial With New

Early Results of Phase 1 Trial With New Anti-HER2 Radionuclide Conjugate

✍ Meredith, R.F.; Torgue, J.; Azure, M.T.; Shen, S.; Banaga, E.; Carlisle, R.; Bun 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Immunotherapy with MVA-BN®-HER2 induces

Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells

✍ Stefanie J. Mandl; Ryan B. Rountree; Katie Dalpozzo; Lisa Do; John R. Lombardo; 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 691 KB

Correction: Phase I clinical study of th

Correction: Phase I clinical study of the recombinant antibody-toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas

✍ Gunter von Minckwitz, Sebastian Harder, Sascha Hövelmann… 📂 Article 📅 2006 🏛 BioMed Central 🌐 English ⚖ 33 KB

5020 Pharmacokinetics (PK), safety, and

5020 Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial results

✍ H. Burris III; S. Vukelja; I. Krop; S. Modi; B. Klencke; S. Girish; M.X. Sliwkow 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Results of the first phase 1 clinical tr

Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients : United States Military Cancer Institute Clinical Trials Group Study I-04

✍ Mark G. Carmichael; Linda C. Benavides; Jarrod P. Holmes; Jeremy D. Gates; Eliza 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 1 views